NRC Health (NRC) Stock Sinks As Margin Compression Deepens Earnings Pain

NRC Health came into this earnings print with a premium P/E multiple and a stock that had already been soft in recent weeks. The Q2 2026 report flipped that setup. The share price dropped about 18% to US$18.34 in regular trading, as investors reacted to an earnings loss in the quarter and a visibly thinner net profit margin over the last 12 months.

For a company often treated as a quality healthcare software play, the gap between a rich valuation and a quarter that produced a net income loss of US$3.283 million is what hit hardest. The detailed story behind that squeeze on profits comes next.

Is NRC Health now a genuine value opportunity after this sharp derating, or just an expensive stock with pressured margins and a one off hit to earnings? Compare the current P/E, DCF fair value estimate and earnings profile in our valuation analysis for NRC Health.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$35.392 million vs. US$34.038 million (up about 4%)
• Net Income/Loss (Q2 2026 vs. Q2 2025): loss of US$3.283 million vs. loss of US$0.19 million (loss widened)
• Basic EPS (Q2 2026 vs. Q2 2025): loss of US$0.15 per share vs. loss of US$0.01 per share (loss per share increased)
• Net Profit Margin (Trailing 12 Months vs. Prior Year): 4% vs. 12.7% (margin compressed), driven in part by a one off loss of US$6.8 million

Prefer clean charts over scrolling through another block of earnings text? See NRC Health's full valuation picture laid out in a simple visual dashboard in our company report for NRC Health.

NRC Health: Revenue Resilience Versus Profit Pressure

NRC Health still shows some support for a constructive view. Total revenue moved to US$35.392 million from US$34.038 million, while Total Recurring Contract Value of US$151.9 million grew 11% year on year, helped by mid teens growth in Experience and solid Governance Institute bookings. Adjusted EBITDA margin of 27% held firm quarter on quarter despite heavier spend and an accounting headwind on certain reputation products. For a subscription led model, that mix of recurring contract growth and stable core margin suggests the underlying client demand story is intact.

Bear Case: Margin Compression And Market Skepticism

The bearish angle also has real support. NRC Health swung to a quarterly net loss of US$3.283 million and trailing net margin compressed from 12.7% to 4%, even allowing for a US$6.8 million one off charge. Reported basic EPS moved from a small loss to a larger loss, while the stock price fell about 18% on the day and is down roughly 15% over one and three months. That reaction shows investors are focusing on pressured profitability and near term implementation and tax noise, rather than contract wins alone.

Compare how NRC Health’s recurring contract growth stacks up against the sharper earnings loss, and see whether analysts think this operational progress justifies the recent 17.91% share price drop using the consensus price target analysis for NRC Health.

Stay Ahead With Simply Wall St

If the mix of recurring contract growth and a sharp earnings loss at NRC Health has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a more attractive entry point. Once you decide to take a position, keep on top of what matters with the Portfolio Command Center that focuses your view on key developments, not day to day noise. For a longer term view, tap into the Community to see how other investors are interpreting the same data and risks. By spotting potential catalysts and pressure points early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond NRC Health?

Fresh stock ideas can start moving fast once momentum builds. Use carefully filtered lists to spot potential breakouts under the radar for now. Do not delay and get in early.

• Chase potential breakout quality by scanning a curated 48 high quality undervalued stocks that screens for strong cash generation and balance sheets before the crowd catches on.
• Ride structural tech momentum by reviewing 56 AI infrastructure stocks that focus on companies supplying the picks and shovels for large scale AI build outs while it still matters.
• Target resilient balance sheets by working through the list of solid balance sheet and fundamentals stocks (48 results) that highlights financially robust stocks investors may overlook until prices are already flying.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com